Categories Earnings, Health Care

Biogen (NASDAQ: BIIB): Q4 2019 Earnings Snapshot

— Biogen Inc. (NASDAQ: BIIB) reported its fourth-quarter 2019 adjusted earnings of $8.34 per share versus $8.02 per share expected.

— Total revenues increased by 4% to $3.67 billion versus $3.54 billion expected.

Biogen (BIIB) Q4 2019 Earnings Snapshot

— Total product revenues rose by 4% driven by growth in multiple sclerosis drugs, spinal muscular atrophy drug Spinraza, biosimilars Benepali, Imraldi, and Flixabi.

— Research and development expense rose by 13% due to the inclusion of charges related to Samsung Bioepis transaction, related to the option exercise with Ionis Pharmaceuticals, and related to collaboration agreements with CAMP24 Therapeutics and Catalyst Biosciences.

— Looking ahead into the full year 2020, the company expects revenue in the range of $14-14.3 billion and adjusted earnings in the range of $31.50-33.50 per share. Analysts expect EPS of $33.03 on revenue of $14.06 billion.

— The earnings are anticipated to be in the range of $29.50-31.50 per share for the full year.

Follow our Google News edition to get the latest stock market, earnings and financial news at your fingertips.

Also Read:  Cantel Medical Corp. (NYSE: CMD) Q4 2020 Earnings Call Transcript

Most Popular

Costco (COST) Q4 earnings, revenue top expectations

Retail giant Costco Wholesale Corporation (NASDAQ: COST) reported higher earnings and revenues for the fourth quarter of 2020, reflecting a marked increase in merchandise sales. The results also topped analysts’

Can Cintas (CTAS) take forward virus-driven shift in sales trend?

The disruption caused by coronavirus has affected almost all sectors except business service providers like Cintas Corporation (NASDAQ: CTAS), which is busy helping clients maintain hygiene and safety during the

Rite Aid’s (RAD) loss narrows in Q2 2021

Rite Aid Corporation (NYSE: RAD) reported a narrower loss in the second quarter of 2021. Net loss shrank to $0.25 per share in the recently ended quarter from $1.49 per

One thought on “Biogen (NASDAQ: BIIB): Q4 2019 Earnings Snapshot

Comments are closed.

Top